Body Fat Reduction Market Outlook:
Body Fat Reduction Market size was over USD 11.34 billion in 2025 and is anticipated to cross USD 26.12 billion by 2035, growing at more than 8.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of body fat reduction is estimated at USD 12.23 billion.
out of these were living with obesity-related ailments. The study also estimates that improper diet and inadequate physical activities are set to double the prevalence rate in the coming years. Thus, a rise in obesity rates will boost the sales of body fat reduction technologies in the coming years.
Considering this a serious health challenge, many medical research organizations and companies are investing in R&D activities for accreted government approvals and introducing safe solutions to reduce body fat. For instance, in May 2023, Apyx Medical Corporation received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Medical’s Renuvion. This new APR Handpiece is estimated to be effective for the coagulation of soft tissues following liposuction. Furthermore, in July 2024, scientists from the University of California San Fransisco (UCSF) revealed that altering a protein in white fat cells can lead to the development of a new class of weight loss drugs.
Leading companies are employing various strategies including new product launches and acquisitions to maximize their revenue shares. For instance, in October 2024, AbbVie Inc. revealed its financial results for the third quarter ended September FY 24. The global net revenue reached USD 14.46 billion with an increase of 3.8% and 4.9%, on reported bases and operational basis, respectively. Whereas, the worldwide net revenue of the aesthetics portfolio is valued at USD 1.23 billion with a 1.8% rise on an operational basis. These statistics highlight that the company is earning positive shares from its aesthetic portfolio, contributing to the overall body fat reduction market growth.
